ArticleViruses2022
Epipharyngeal Abrasive Therapy (EAT) Has Potential as a Novel Method for Long COVID Treatment.
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 31 citations in OpenAlex.
- Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial.Scientific reports · 2025Trial
- Safety and Changes in Health-Related Quality of Life After Epidural Oxygen Injection for Long COVID/Post-COVID Syndrome: A Multicenter Retrospective Study.Journal of clinical medicine · 2026Article
- Association Between Granular Changes on Epipharyngeal Endoscopy and Allergen Sensitization in Chronic Epipharyngitis.Reports (MDPI) · 2026Article
- Article
- Respiratory Oscillometry Findings in Chronic Epipharyngitis.Reports (MDPI) · 2026Article
- Th17/Treg Imbalance Reveals Local-Systemic Immune Dissociation in Nasopharyngeal Inflammation and Its Association with Endoscopic Severity.Medicina (Kaunas, Lithuania) · 2026Article
- Observational
- A narrative review of SARS-CoV-2 variants and long COVID.Journal of thoracic disease · 2026Review
- Article
- Review
- Retracted: Chronic Epipharyngitis Treated with Epipharyngeal Abrasion Therapy: Symptoms, Diagnosis, Pathogenesis, and Treatment Outcomes.JMA journal · 2025Review
- Spatial transcriptomics of the epipharynx in long COVID identifies SARS-CoV-2 signalling pathways and the therapeutic potential of epipharyngeal abrasive therapy.Scientific reports · 2025Article
- Article
- Review
- A Comparative Review of the Terms Epipharyngitis and Nasopharyngitis in Medical Literature.Cureus · 2024Review
- Differences Between Patients With Chronic Epipharyngitis With and Without Previous COVID-19 Infection.Cureus · 2024Article
- Treatment of long COVID complicated by postural orthostatic tachycardia syndrome-Case series research.Journal of general and family medicine · 2024Article
- Article
- Article
- LitCovid in 2022: an information resource for the COVID-19 literature.Nucleic acids research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 often causes sequelae after initial recovery, referred to collectively as long COVID. Long COVID is considered to be caused by the persistence of chronic inflammation after acute COVID-19 infection. We found that all long COVID patients had residual inflammation in the epipharynx, an important site of coronavirus replication, and some long COVID symptoms are similar to those associated with chronic epipharyngitis. Epipharyngeal abrasive therapy (EAT) is a treatment for chronic epipharyngitis in Japan that involves applying zinc chloride as an anti-inflammatory agent to the epipharyngeal mucosa. In this study, we evaluated the efficacy of EAT for the treatment of long COVID. The subjects in this study were 58 patients with long COVID who were treated with EAT in the outpatient department once a week for one month (mean age = 38.4 ± 12.9 years). The intensities of fatigue, headache, and attention disorder, which are reported as frequent symptoms of long COVID, were assessed before and after EAT using the visual analog scale (VAS). EAT reduced inflammation in the epipharynx and significantly improved the intensity of fatigue, headache, and attention disorder, which may be related to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). These results suggest that EAT has potential as a novel method for long COVID treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.